Fredag 27 December | 14:56:37 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-10-24 08:00 Kvartalsrapport 2025-Q3
2025-07-11 08:00 Kvartalsrapport 2025-Q2
2025-05-22 N/A Årsstämma
2025-04-17 08:00 Kvartalsrapport 2025-Q1
2025-02-07 08:00 Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-09-23 - Extra Bolagsstämma 2024
2024-07-05 - Kvartalsrapport 2024-Q2
2024-05-17 - X-dag ordinarie utdelning NICA 0.00 SEK
2024-05-16 - Årsstämma
2024-04-26 - Kvartalsrapport 2024-Q1
2024-02-09 - Bokslutskommuniké 2023
2023-10-27 - Kvartalsrapport 2023-Q3
2023-07-07 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning NICA 0.00 SEK
2023-05-04 - Årsstämma
2023-04-28 - Kvartalsrapport 2023-Q1
2023-02-10 - Bokslutskommuniké 2022
2022-11-11 - Kvartalsrapport 2022-Q3
2022-09-15 - Extra Bolagsstämma 2022
2022-08-19 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning NICA 0.00 SEK
2022-06-02 - Årsstämma
2022-04-29 - Kvartalsrapport 2022-Q1
2022-02-08 - Bokslutskommuniké 2021
2021-10-29 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning NICA 0.00 SEK
2021-05-27 - Årsstämma
2021-05-07 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-10-30 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-29 - X-dag ordinarie utdelning NICA 0.00 SEK
2020-05-28 - Årsstämma
2020-02-26 - Extra Bolagsstämma 2020
2020-02-24 - Kvartalsrapport 2020-Q1
2020-02-07 - Bokslutskommuniké 2019
2019-10-25 - Kvartalsrapport 2019-Q3
2019-08-27 - Kvartalsrapport 2019-Q2
2019-05-31 - X-dag ordinarie utdelning NICA 0.00 SEK
2019-05-29 - Årsstämma
2019-05-10 - Kvartalsrapport 2019-Q1
2019-02-15 - Bokslutskommuniké 2018
2018-11-23 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-06-01 - X-dag ordinarie utdelning NICA 0.00 SEK
2018-05-31 - Årsstämma
2018-04-25 - Kvartalsrapport 2018-Q1
2018-02-23 - Bokslutskommuniké 2017
2017-11-23 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-06-02 - X-dag ordinarie utdelning NICA 0.00 SEK
2017-06-01 - Årsstämma
2017-05-19 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016
2016-11-17 - Kvartalsrapport 2016-Q3
2016-09-12 - Extra Bolagsstämma 2016
2016-08-26 - Kvartalsrapport 2016-Q2
2016-06-01 - X-dag ordinarie utdelning NICA 0.00 SEK
2016-05-31 - Årsstämma
2016-05-20 - Kvartalsrapport 2016-Q1
2016-02-19 - Bokslutskommuniké 2015
2015-11-26 - Kvartalsrapport 2015-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Nanologica är ett life science tools-bolag som utvecklar, tillverkar och säljer avancerade insatsvaror till läkemedelsproducerande företag. Nanologicas silikabaserade produkter är speciellt framtagna för rening av peptidläkemedel, såsom insulin och GLP-1-analoger. Nanologica verkar på en global nischmarknad för läkemedel för behandling av diabetes och obesitas. Nanologica grundades 2004 och har sitt huvudkontor i Södertälje.
2024-09-23 15:07:00

Today Nanologica AB (publ) held an extraordinary general meeting whereby the following resolutions were adopted.

For more detailed information on the content of the resolutions, please see the complete notice of the extraordinary general meeting that is available on the company’s website, www.nanologica.com.
 
Determination of the number of board members, election of a new board member and determination of remuneration
The general meeting resolved to expand the board of directors from five to six members and to elect Alexandra Blomberg Montgomery as a new member of the board of directors for the period until the end of the next annual general meeting. Furthermore, it was resolved that Alexandra Blomberg Montgomery shall receive remuneration on par with the other board members, adjusted to account for the fact that she assumes the position later in the year.
 
Resolution regarding approval of the board of directors’ resolution to issue units with preferential rights for existing shareholders
The general meeting resolved, in accordance with the proposal presented by the board of directors under item 7 on the agenda, to approve the board of directors’ resolution on 29 August 2024 to issue new units with preferential rights for existing shareholders.
 
The rights issue comprises a new issue of a maximum of 11,044,654 units. The rights issue entails an increase of the company's share capital by a maximum of SEK 5,522,327, of which a maximum of SEK 4,417,861.60 is attributable to an increase due to the issue of shares and a maximum of SEK 1,104,465.40 is attributable to an increase due to the issue of warrants.
 
Each unit consists of four (4) shares and one (1) warrant of series 2024/2025. This means that a maximum of 44,178,616 new shares and a maximum of 11,044,654 new warrants can be issued. Each unit is issued at a price of SEK 9.00 per unit, corresponding to a subscription price of SEK 2.25 per newly issued share. The warrants are issued free of charge. The right to subscribe for new units shall with preferential right be granted to those who are registered as shareholders in the company on the record date for the new share issue. One (1) existing share on the record date September 25, 2024 entitles to one (1) unit right. Four (4) unit rights entitle the holder to subscribe for one (1) unit. In addition, investors are offered the opportunity to register for subscription of units without the support of unit rights. The subscription period is expected to run between September 30 2024 to October 14, 2024.
 
Since the general meeting resolved in accordance with the board's proposal under item 7 on the agenda, it was noted that the alternative proposal under item 8 on the agenda would be withdrawn.
 
Resolution on reduction of the share capital
The general meeting resolved to reduce the company's share capital by a maximum of SEK 4,417,861.60 for allocation to non-restricted equity. The share capital shall be reduced by an amount in SEK corresponding to the amount by which the share capital increases through the resolved rights issue, but only to the extent that the share capital increase is attributable to newly issued shares. An increase in share capital that may occur due to newly issued warrants being exercised for subscription of shares shall not be taken into account. The reduction shall be carried out without the cancellation of shares.
 
Resolution on authorization for the board of directors
The general meeting further resolved to authorize the board of directors to, on one or more occasions during the period until the next annual general meeting, with deviation from the shareholders' preferential rights, resolve on a new issue of not more than 2,222,222 units consisting of 8,888,888 shares and 2,222,222 warrants. Each unit shall consist of four (4) shares and one (1) warrant issued free of charge. The board of directors shall be able to decide on an issue with a provision for contribution in kind, set-off or otherwise with conditions in accordance with the Swedish Companies Act.
 
An issue of units in accordance with the authorization shall be made at a price of SEK 9.00 per unit, corresponding to SEK 2.25 per share. The warrants shall be issued free of charge.
 
The reason why the board of directors shall be able to resolve on an issue with deviation from the shareholders' preferential rights is that the board of directors shall be able to accommodate a possible oversubscription in the rights issue and take advantage of the opportunity to provide the company with additional capital in a time and cost-effective manner and/or expand the circle of owners with one or more owners of strategic importance to the company.